MedTrace Logo

The Added Value of Tissue or Liquid Biopsy NGS Profiling in Advanced Solid Tumor Treatment Decisions.

NCT07713550 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2026-07-20

No results posted yet for this study

Summary

A total of 550 patients with metastatic solid tumors or primary CNS malignancy will be recruited on a first come first serve basis at one of the 14 participating centers : UZL, UZG, Imelda, ZAZ, AZ Klina, CHU Liège, GHdC, CHU UCL Namur, IJB, UZB, CUSL, UZA, VITAZ and Jessa Zh..

\> 500 patients with tissue available will undergo CGP centrally at UZ Leuven (Roche AVENIO Tumor Tissue CGP kits, Novaseq platform).

\> 50 patients without tissue available will undergo liquid biopsy testing at Foundation Medicine (FoundationOne Liquid CDx).

The sequencing data generated by UZ Leuven laboratory will then be further analysed (secondary and tertiary analysis) by one of the eight laboratories participating in the study: UZL, UZG, IJB, CUSL, IPG, UZA, Jessa zh. and CHU Liège.

Conditions

  • Advanced Solid Tumor Cancer
  • Primary CNS Tumors

Interventions

DIAGNOSTIC_TEST

Comprehensive NGS testing

To determine the Added Value of Tissue and Liquid Biopsy NGS profiling in Advanced Solid Tumor Treatment Decisions: The Belgian PRECISION study of the BSMO in collaboration with the Cancer Center of Sciensano (GeNeo 2.0)

Sponsors & Collaborators

  • The Belgian Society of Medical Oncology

    lead OTHER

Principal Investigators

  • Philippe Aftimos, Oncologist · Jules Bordet Institute

  • Kevin Punie, Oncologist · ZAS

  • Jacques de Grève, Oncologist · Universitair Ziekenhuis Brussel

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-22
Primary Completion
2027-05-31
Completion
2029-04-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07713550 on ClinicalTrials.gov